|
|
||||||||
-Palmitoyl-lysine Increases the Life Span of Functional Presentation to Cytotoxic T Cells1





*
Unité Mixte de Recherche 8525, Centre National de la Recherche Scientifique-Lille II University and Institut Pasteur de Lille, Lille, France;
Institut National de la Santé et de la Recherche Médicale Unité 445, Institut Cochin de Génétique Moléculaire, Paris, France; and
Institut für Organische Chemie, Universität Tübingen, Tübingen, Germany
The delineation of the minimal requirements for efficient delivery
of functional cytotoxic epitopes into APC could be a step toward the
definition of "minimal length" lipopeptides for the modulation of
CTL activity. Several analogues of the HLA-A*0201-restricted HIV-1
polymerase (pol476484) minimal cytotoxic epitope were
obtained by modifying P0, P1, or P10 positions by a single
N
-palmitoyl-lysine residue. The use of
fluorescent derivatives confirmed the cell-permeating activities and
suggested that a P0- and a P1-modified lipopeptide possessing ionizable
extremities fulfills the structural requirements for MHC loading. The
expressions of HLA-peptide complexes at the surface of TAP-deficient
cells incubated with the parent epitope or lipopeptide derivatives were
compared, in terms of intensity and stability. Both lipopeptides
induced a considerably prolonged expression of conformationally correct
complexes, which were dependent on the integrity of the exocytosis
pathway, suggesting a dynamic mechanism of formation or reloading of
the complexes from an intracellular pool. The agonistic activities of
the different HLA-peptide complexes were evaluated using two
independent T cell lines from HIV-infected donors. We report that a
lipodecapeptide obtained by N-terminal addition of a
N
-palmitoyl-lysine to the
pol476484 epitope was able to increase the life span of
functional presentation to cytotoxic T cells specific for the parent
peptide.
This article has been cited by other articles:
![]() |
M. Bastian, T. Braun, H. Bruns, M. Rollinghoff, and S. Stenger Mycobacterial Lipopeptides Elicit CD4+ CTLs in Mycobacterium tuberculosis-Infected Humans J. Immunol., March 1, 2008; 180(5): 3436 - 3446. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Pfender, S. Grosch, G. Roussel, M. Koch, E. Trifilieff, and J. M. Greer Route of Uptake of Palmitoylated Encephalitogenic Peptides of Myelin Proteolipid Protein by Antigen-Presenting Cells: Importance of the Type of Bond between Lipid Chain and Peptide and Relevance to Autoimmunity J. Immunol., February 1, 2008; 180(3): 1398 - 1404. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. F. Lau, G. Deliyannis, W. Zeng, A. Mansell, D. C. Jackson, and L. E. Brown Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines Int. Immunol., December 1, 2006; 18(12): 1801 - 1813. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, A. Issagholian, E. A. Berg, J. B. Fishman, A. B. Nesburn, and L. BenMohamed Th-Cytotoxic T-Lymphocyte Chimeric Epitopes Extended by N{varepsilon}-Palmitoyl Lysines Induce Herpes Simplex Virus Type 1-Specific Effector CD8+ Tc1 Responses and Protect against Ocular Infection J. Virol., December 15, 2005; 79(24): 15289 - 15301. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Andrieu, J.-F. Desoutter, E. Loing, J. Gaston, D. Hanau, J.-G. Guillet, and A. Hosmalin Two Human Immunodeficiency Virus Vaccinal Lipopeptides Follow Different Cross-Presentation Pathways in Human Dendritic Cells J. Virol., December 20, 2002; 77(2): 1564 - 1570. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Deliyannis, D. C. Jackson, N. J. Ede, W. Zeng, I. Hourdakis, E. Sakabetis, and L. E. Brown Induction of Long-Term Memory CD8+ T Cells for Recall of Viral Clearing Responses against Influenza Virus J. Virol., March 27, 2002; 76(9): 4212 - 4221. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Greer, B. Denis, R. A. Sobel, and E. Trifilieff Thiopalmitoylation of Myelin Proteolipid Protein Epitopes Enhances Immunogenicity and Encephalitogenicity J. Immunol., June 1, 2001; 166(11): 6907 - 6913. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |